Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,116.00
Bid: 12,114.00
Ask: 12,116.00
Change: 10.00 (0.08%)
Spread: 2.00 (0.017%)
Open: 12,166.00
High: 12,188.00
Low: 12,112.00
Prev. Close: 12,106.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 5-Europe enacts new curbs as COVID surges in absence of vaccine

Tue, 27th Oct 2020 10:57

(Adds Spain, EU)

* Anti-restriction protests turn violent in Italy

* France warns of "difficult decisions" ahead

* Trump pushes vaccines, but none yet available

By Crispian Balmer

ROME, Oct 27 (Reuters) - European governments moved on
Tuesday to impose new curbs to try to rein in a fast-growing
surge of coronavirus infections and provide economic balm to
help businesses survive the pandemic.

World leaders face an increasingly difficult task holding
the disease at bay while keeping their economies afloat as they
pin their hopes on as-yet unproven vaccines.

"We are dealing with exponential growth," German Economy
Minister Peter Altmaier told a virtual German-French economic
conference in Berlin. "In Germany the number of new infections
is rising by 70-75% compared to the week before."

The United States, Russia, France, Sweden, Poland and other
countries have registered record numbers of infections in recent
days as autumn turns to winter in the Northern Hemisphere and
people socialise indoors where the risk of infection is higher.

More than 43.4 million people have been infected by the
coronavirus globally and 1,158,056? have died, according to a
Reuters tally, with the United States leading the way in the
number of infections and deaths.

Hundreds of protesters took to the streets across Italy on
Monday to vent their anger at the latest round of restrictions,
including early closing for bars and restaurants, with
demonstrations in some cities turning violent.

In the financial capital Milan, youths hurled petrol bombs
at police, who responded with volleys of tear gas. In nearby
Turin, luxury shops had their windows smashed and some were
ransacked, leading to the arrest of 10 rioters.

In France, Interior Minister Gerald Darmanin warned the
country to prepare for "difficult decisions" after some of the
strictest restrictions currently in place anywhere in Europe
have failed to halt the spread of the disease.

The Czech government will ask lawmakers to extend its
emergency powers until Dec. 3, Prime Minister Andrej Babis said
on Tuesday, as it tries to stem one of the strongest surges in
infections in Europe.

BRAIN FUNCTION AFFECTED

There have been at least 8.54 million reported infections
and 251,000 deaths caused by coronavirus in Europe so far,
according to latest Reuters data. The continent registered a
record 230,892 new cases on Monday, up from 67,739 on Oct. 1.

Authorities in Russia, which with 1.55 million infections
has the world's fourth largest COVID-19 case load, ordered
people to wear facemasks in some public places and asked
regional authorities to consider shutting bars and restaurants
overnight.

New infections in Belgium, among the hardest-hit countries
in Europe, hit a high of more than 18,000 on Oct. 20, almost a
10-fold increase from the high of a spring wave of the pandemic.

The country is expected to decide by this weekend whether a
return to a nationwide lockdown is required.

Even Germany, widely praised for its initial response to the
pandemic, signalled concern on Tuesday over rising infections,
with Altmaier saying the country was likely to reach 20,000
cases a day by the end of this week.

Spain's wine-producing region of La Rioja ordered the
closure of restaurants and bars in its two largest towns for a
month. A nationwide curfew has been in place since Sunday.

A gauge of global stock markets fell and the U.S. dollar
slipped on Tuesday as investors grappled with a surge in
coronavirus cases and uncertainty over the impending U.S.
election.

Adding to the gloomy sentiment, a new study by Imperial
College London found that antibodies against the new coronavirus
declined rapidly in the British population during summer,
suggesting protection after infection may not be long-lasting.
Recovering patients may also suffer a decline in
brain function, researchers warned.

In the United States, the number of hospitalised COVID-19
patients is at a two-month high, straining health care systems
in some states. The U.S. death toll leads the world at more than
225,300.

"Until November 4th., Fake News Media is going full on
Covid, Covid, Covid," President Donald Trump, facing a tough
re-election battle on Nov. 3, tweeted on Tuesday in an
often-repeated refrain without offering evidence. "We are
rounding the turn. 99.9%."

Trump has often promoted vaccines as the answer, but none
has yet won international approval. Russia in August became the
first country to grant regulatory approval for a vaccine after
less than two months of human testing, raising eyebrows among
sceptical scientists in the West.

A vaccine being developed by the University of Oxford and
AstraZeneca Plc produces an immune response in both old
and young adults, the company said on Monday, raising hopes of a
path out of the gloom.

But only a share of the EU population can be inoculated
before 2022, should a vaccine become available, EU officials
said in an internal meeting on Tuesday.

The warning comes in spite of the fact that the 27-nation
bloc, with a population of 450 million, has secured more than a
billion doses of potential vaccines from three drugmakers.

(Reporting by Reuters bureaux; Writing by Crispian Balmer and
Nick Macfie; Editing by Alison Williams and Jon Boyle)

More News
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.